Back to top
more

Envista (NVST)

(Delayed Data from NYSE)

$19.41 USD

19.41
3,595,288

+0.74 (3.96%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $19.40 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Envista (NVST) Beats Q4 Earnings and Revenue Estimates

Envista (NVST) delivered earnings and revenue surprises of 9.52% and 2.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Envista (NVST) Could Beat Earnings Estimates Again

Envista (NVST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Envista (NVST) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Envista (NVST) Gets FDA 510 (k) Approval for N1 Implant System

Envista (NVST) noted that the Nobel Biocare N1 system represents a significant step further in patient-centric dental implant solutions.

New Strong Sell Stocks for December 6th

BYND, NVST, FSTR, ZBH, and PHR have been added to the Zacks Rank #5 (Strong Sell) List on December 6, 2021.

New Strong Sell Stocks for November 29th

DVA, NVST, WWD, PHR, and ROAD have been added to the Zacks Rank #5 (Strong Sell) List on November 29, 2021

Envista (NVST) Q3 Earnings Beat Estimates

Envista (NVST) delivered earnings and revenue surprises of 12.50% and -10.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Envista (NVST) to Report a Decline in Earnings: What to Look Out for

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Veeva Systems' (VEEV) Deal to Enhance Digital Clinical Trials

Veeva Systems' (VEEV) partnership with Leo Pharma to significantly boost the clinical trial process for patients, sites and sponsors.

Here's Why You Should Hold on to NextGen (NXGN) Stock Now

NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. However, intense competition woes linger.

Here's Why You Should Add Neogen (NEOG) to Your Portfolio Now

Investors are optimistic about Neogen (NEOG) on strength in its Food Safety and Animal Safety business segments.

Thermo Fisher (TMO) Expands Biologics Network With New Facility

Thermo Fisher's (TMO) Lengnau site will offer biopharma companies a pathway from development to large-scale production.

Here's Why You Should Retain CVS Health (CVS) Stock For Now

Investors are optimistic about CVS Health (CVS) on growth in the company's specialty digital solutions and a bullish 2021 outlook.

Bio Rad (BIO) Global Growth Strong, Expenses Continue to Rise

Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.

Here's Why You Should Invest in Patterson Companies (PDCO) Stock

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.

Cardinal Health's (CAH) Unit to Aid Canadian Healthcare System

Cardinal Health's (CAH) subsidiary to support the Canadian Healthcare system against COVID-19 with vaccination policy.

Cardiovascular Systems (CSII) Treats 1st Patient With ViperCross

Cardiovascular Systems' (CSII) ViperCross offers the correct balance of support and flexibility to navigate tortuous anatomy and cross challenging lesions.

Here's Why You Should Invest in West Pharmaceutical (WST) Now

West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

PacBio (PACB) Partners with ERGA, Boosts Biodiversity Research

PacBio's (PACB) collaboration with ERGA will help scientists to take the first important step toward creating high-quality genetic maps of each plant and animal species in a reliable manner.

Quest Diagnostics' (DGX) Base Volumes Rise, Testing Recovers

Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).

Medtronic (MDT) Gets CE Mark for Radial Artery Access Portfolio

Medtronic's (MDT) Rist Radial Access Catheters are indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature.

NEOGEN (NEOG) Inks Genomic Selection Deal With Hendrix

Hendrix Genetics with the help of NEOGEN's (NEOG) Genomics will be able to genotype the elite animals in the population.

Here's Why You Should Invest in Quest Diagnostics (DGX) Now

Investors are optimistic about Quest Diagnostics (DGX) backed by its strong second-quarter performance and recovery in the base testing business.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

Investors are optimistic about Medtronic (MDT) owing to new product flow and strong market share gain across the company's businesses.

Medtronic (MDT) Hugo RAS System Used for 1st Clinical Procedure

Medtronic's (MDT) Hugo RAS system is a modular, multi-quadrant platform intended for a broad range of soft-tissue procedures.